RALEIGH, N.C., Aug. 21 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR) today announced that it has received CE Mark approval for
Dermabond(TM), its topical tissue cohesive used to close wounds from skin
lacerations and incisions. The CE Mark allows Dermabond(TM) to be marketed in
each of the countries comprising the European Union.
In March 1996, the Company entered into a marketing agreement with
Ethicon, Inc., a subsidiary of Johnson & Johnson, for exclusive worldwide
marketing and distribution of Dermabond(TM). The CE Mark will allow CLOSURE
Medical to ship Dermabond(TM), manufactured in the Company's U.S. facility, to
Ethicon for launch in European Union countries.
"We are extremely pleased to receive the CE Mark for tissue cohesives for
ophthalmic and topical applications. This approval is the result of a
Company-wide commitment to excellence in our quality assurance systems," said
Bob Toni, President and Chief Executive Officer. "Receiving the CE Mark is
also an important milestone, since it will enable the Company to begin a full-
scale marketing program for our lead product."
CLOSURE Medical develops, commercializes and manufactures medical cohesive
products based on its proprietary cyanoacrylate technology. CLOSURE's
nonabsorbable products may be used to replace sutures and staples for certain
topical wound closure applications, while its absorbable products can
potentially be used as surgical sealants and adhesives for internal wound
closure and management. Currently marketed products include Octyldent(R),
used in conjunction with antibiotics to treat adult periodontal disease, and
Nexaband(R), a line of topical adhesives used in veterinary wound closure and
management.
This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements. These factors
include, but are not limited to the early stage of commercialization of the
Company products; the need for regulatory approval and effects of governmental
regulation; technological uncertainties; dependence on marketing partners; and
dependence on patents and trade secrets, as well as those detailed in the
Company's Annual Report on Form 10-K for the year ended December 31, 1996
filed with the Securities and Exchange Commission.
To receive CLOSURE's latest news release and other corporate documents via
FAX -- at no cost -- dial 1-800-PRO-INFO. Use Company's ticker: CLSR.
SOURCE CLOSURE Medical Corporation
 back to top
CONTACT:
Robert V. Toni, President & CEO, or J. Blount
Swain, CFO, both of CLOSURE Medical Corporation, 919-876-7800; or
General: Paul G. Henning, or Analysts: Brian Gill, or Media:
Deanne Eagle, all of The Financial Relations Board, 212-661-8030,
for CLOSURE Medical Corporation
|
